On October 12, 2006, Connolly, Stephen; Skrinjar, Marco published a patent.Quality Control of 3-(2-Methoxyphenoxy)benzaldehyde The title of the patent was Preparation of novel diazaspiroalkanes and their use for treatment of CCR8 mediated diseases. And the patent contained the following:
The title compounds I [R = (un)substituted pyridin-2-one or N-alkyl pyridin-2-one; R1 = II, III; R3, R4 = OMe, OEt], useful in treating CCR8 mediated diseases such as asthma, COPD and rhinitis, were prepared E.g., a multi-step synthesis of IV, starting from tert-Bu 3,9-diazaspiro[5.5]undecane-3-carboxylate hydrochloride and 2-(2-methoxyphenoxy)benzaldehyde, was given. IV showed IC50 of 0.044 μM against human recombinant chemokine CCR8 receptor binding. Pharmaceutical compositions containing compounds I and their use in therapy are disclosed. The experimental process involved the reaction of 3-(2-Methoxyphenoxy)benzaldehyde(cas: 66855-92-3).Quality Control of 3-(2-Methoxyphenoxy)benzaldehyde
The Article related to diazaspiroalkane diazaspiroundecane preparation chemokine ccr8 mediated disease treatment, antiasthmatic diazaspiroalkane diazaspiroundecane preparation, chronic obstructive pulmonary disease diazaspiroalkane diazaspiroundecane preparation, rhinitis diazaspiroalkane diazaspiroundecane preparation and other aspects.Quality Control of 3-(2-Methoxyphenoxy)benzaldehyde
Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem